Introdução: O envolvimento hepático na doença celíaca (DC) é amplamente reconhecido e atualmente é uma das manifestações extra-intestinais mais freqüentes. Com o advento de marcadores sorológicos de elevada especificidade e sensibilidade, sobretudo o anticorpo antiendomísio (EMA), a DC tem sido descrita em associação a várias hepatopatias. Objetivos: caracterizar as formas de triagem de DC em portadores de hepatopatia crônica; caracterizar e estudar os pacientes cujo diagnóstico de DC foi realizado durante a investigação de uma doença hepática; pesquisar a reatividade do antiendomísio em pacientes com hepatite auto-imune, cirrose biliar primária, colangite esclerosante primária e hipertensão portal não cirrótica; avaliar o comportamento da doença hepática na vigência de dieta sem glúten. Métodos: Os pacientes foram triados pela detecção dos anticorpos anti-reticulina e anticorpo antimatriz extracelular durante a rotina de imunofluorescência de pesquisa dos auto-anticorpos hepáticos; pela presença de manifestações de DC em hepatopatas crônicos, pelo aspecto endoscópico sugestivo de DC e pela pesquisa sistemática do EMA nas patologias referidas anteriormente. Todos os pacientes foram submetidos à pesquisa do EMA, anti-reticulina IgG ou antimatriz de fibroblastos IgG na presença de deficiência de IgA. Em caso de positividade desses marcadores, foram submetidos à endoscopia digestiva alta para biópsia intestinal e caracterizados do ponto de vista clínico, laboratorial e histopatológico. A evolução desses dados permitiu a caracterização da evolução da doença hepática e da doença celíaca a partir da introdução da dieta sem glúten. Resultados: Foram identificados 43 pacientes com auto-anticorpos relacionados à DC (em 42 o EMA IgA e em um o antimatriz extracelular IgG em associação com deficiência de IgA). A rotina de pesquisa de auto-anticorpos hepáticos identificou 31 pacientes; seis apresentavam hepatopatia crônica e manifestação de DC; em três o exame endoscópico foi sugestivo de DC e a pesquisa sistemática do EMA foi positiva em três casos. O diagnóstico de DC foi confirmado em 37 de 40 pacientes (92,5%) em que a biópsia intestinal foi realizada. A idade dos pacientes variou de 2 a 68 anos, com mediana de 35 anos. Houve maior prevalência de acometimento no sexo feminino (65%). A DC foi mais prevalente na raça branca (87%), mais foi identificada em quatro mulatos e um negro. As doenças hepáticas mais freqüentes foram hipertransaminasemia criptogênica, hepatite auto-imune, hiperplasia nodular regenerativa e hepatite pelo vírus C. Conclusões: 1) A reatividade do anti-reticulina, a presença de diarréia inexplicada e a análise endoscópica da mucosa duodenal foram as formas de seleção mais efetivas de se identificar a DC em hepatopatas crônicos. 2) A ausência de manifestações clínicas de DC nesse grupo de pacientes foi bastante expressiva. 3) A pesquisa sistemática do EMA em cirrose biliar primaria, hepatite auto-imune, colangite esclerosante primária não contribuiu para o diagnóstico de DC em um número significativo de pacientes, ao contrário do observado no grupo de hipertensão portal não cirrótica, especialmente hiperplasia nodular regenerativa 4) As doenças hepáticas em que mais freqüentemente foi diagnosticada a DC foram a hiperplasia nodular regenerativa, hepatite auto-imune, hipertransaminasemia criptogênica, hepatite pelo vírus C e cirrose biliar primária antimitocôndria negativo. 5) A retirada do glúten da dieta contribuiu de maneira efetiva para normalização das enzimas hepáticas nos casos de hipertransaminasemia criptogênica. Nos grupos de hiperplasia nodular regenerativa, hepatite B e C, cirrose biliar primária, álcool e hepatite auto-imune, o papel da dieta foi de difícil avaliação em razão da interferência da instituição do tratamento específico e da evolução natural da doença hepática de base. / Introduction: The hepatic involvement in Celiac Disease (CD) is well known and widely regarded as a frequent extra-intestinal manifestation. With the advent of highly specific and sensitive serological markers, especially the antiendomysial antibody (EMA), CD has been described in association with several liver conditions. Objectives: To characterize ways for screening patients with chronic liver conditions in order to diagnose CD, to characterize and study patients whose CD diagnoses were performed when investigating hepatic diseases, to test the reactivity of EMA in patients with autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis and non-cirrhotic portal hypertension, to evaluate the course of the hepatic disease in gluten-free diet. Methods: Patients were selected by the detection of antireticulin and anti-extracellular matrix antibodies during routine immunoflourescence determination for hepatic autoantibodies, by the presence of CD manifestations in chronic patients with liver diseases, by the endoscopic aspects suggestive of CD and by systematic search for EMA in the above mentioned pathologies. All patients were submitted to tests for EMA, antireticulin IgG or antimatrix of IgG fibroblasts in IgA deficiency. When testing positive for these markers, patients were submitted to upper digestive endoscopy for intestinal biopsy, and were also characterized from the clinical, laboratorial and histological point of view. The assessment of these data enabled the characterization of the hepatic condition as well as the CD from the onset of a gluten-free diet. Results: 43 patients with autoantibodies related to CD were identified (42 tested positive for IgA EMA and 1 for IgG extracellular antimatrix in the presence of IgA deficiency). Routine determination of hepatic autoantibodies identified 31 patients. Of those, 6 presented chronic liver diseases and CD manifestations. In 3 patients, the endoscopic exam was suggestive of CD; systematic EMA determination was positive in all three cases. The CD diagnosis was confirmed in 37 out of 40 patients (92.5%) that performed intestinal biopsy. Patients aged between 2 and 68 years (median: 35 years). Female patients were most affected (65%). CD was more prevalent in white patients (87%), but was also found in four mulattoes and 1 black person. The most common liver disorders were cryptogenic hypertransaminasemia, autoimmune hepatitis, nodular regenerative hyperplasia and chronic hepatitis C. Conclusions: 1) The reactivity of antireticulin, the presence of unexplained diarrhea and the endoscopic analysis of the duodenal mucous were the most effective ways to identify CD in chronic liver diseases. 2) The absence of CD clinical manifestations in this group of patients was impressive. 3) Contrary to what was observed in the group with non-cirrhotic portal hypertension, especially regenerative nodular hyperplasia, the systematic determination of EMA in primary biliary cirrhosis, autoimmune hepatitis and primary sclerosing cholangitis did not contribute to CD diagnosis in a significant number of patients. 4) CD was most frequently diagnosed in the following liver diseases: cryptogenic hypertransaminasemia, autoimmune hepatitis, nodular regenerative hyperplasia and chronic hepatitis C and negative antimitochondrial primary biliary cirrhosis. 5) The removal of gluten from the diet contributed effectively to bring the hepatic enzymes levels back to normal in cases of cryptogenic hypertransaminasemia. However, the role of diet was difficult to evaluate in nodular regenerative hyperplasia, autoimmune hepatitis, alcohol disease and primary biliary cirrhosis groups due to the nature of the specific treatments and the natural course of the hepatic conditions.

Os objetivos desse estudo foram: 1) Padronizar a pesquisa do anti-tTg, comparando-o com o anticorpo antiendomísio (AAE) e 2) Avaliar as interações da tTg com a fibronectina. 49 celíacos e 124 controles com AAE negativo foram avaliados. O AAE foi pesquisado por imunofluorescência indireta e a reatividade contra a tTg e a fibronectina por ELISA in house e com kits comerciais. O antitTg foi positivo em 46,9% e 100% dos celíacos com o ELISA in house e com kits comerciais, respectivamente. A adição de fibronectina não melhorou a sensibilidade do ELISA. Em conclusão: a detecção do antitTg por ELISA apresenta percentual elevado de falso-positivos, não podendo substituir a pesquisa do AAE / The aims of the current study were: to standardize the detection of anti-tTg antibodies, comparing them with antiendomysial antibodies (EMA) and to assess the interaction of tTg with fibronectin. 49 celiac patients and 124 controls were enrolled. EMA was detected by indirect immunofluorescence reaction and tTg and fibronectin reactivity by in house ELISA and with commercially available kits. Seropositivity to anti-tTG was found in 46.9% and 100% of patients by the in house technique and by commercial kits, respectively. Fibronectin addition did not improve the ELISA sensibility. In conclusion, ELISA for anti-tTG detection has a high rate of false positive results and does not replace EMA

Submitted by Geandra Rodrigues (geandrar@gmail.com) on 2018-07-26T13:26:39Z No. of bitstreams: 1 carlosalbertozanini.pdf: 684996 bytes, checksum: 3de33d6a07e18efb62fbd9b5038b0ea3 (MD5) / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2018-07-26T13:43:56Z (GMT) No. of bitstreams: 1 carlosalbertozanini.pdf: 684996 bytes, checksum: 3de33d6a07e18efb62fbd9b5038b0ea3 (MD5) / Made available in DSpace on 2018-07-26T13:43:56Z (GMT). No. of bitstreams: 1 carlosalbertozanini.pdf: 684996 bytes, checksum: 3de33d6a07e18efb62fbd9b5038b0ea3 (MD5) Previous issue date: 2018-06-25 / A prevalência da doença celíaca (DC) vem aumentando globalmente nas últimas décadas. Indivíduos pertencentes aos chamados grupos de risco, como diabéticos tipo 1 e crianças com baixa estatura, possuem uma probabilidade maior de manifestarem esta doença autoimune do trato intestinal, muitas vezes de forma assintomática, mas que pode evoluir com complicações crônicas, como osteoporose e neoplasias intestinais malignas, se não diagnosticados e tratados de forma precoce. Neste estudo, avaliou-se a prevalência da doença celíaca em crianças com diabetes mellitus tipo I (DM1) ou com baixa estatura (BE), em ambulatório especializado de endocrinologia e em clínica privada pediátrica, em Juiz de Fora, MG. Trata-se de um estudo observacional, transversal, realizado entre janeiro de 2012 e abril de 2016. Um total de 225 pacientes, entre 2 e 16 anos de idade, foram convidados a participar: 104 eram saudáveis (grupo controle - GC), enquanto 58 apresentavam DMl e 63 tinham BE. Desse total, 126 (56%) compareceram para dosagem do anticorpo antitransglutaminase tecidual IgA (TTG IgA) e IgA sérica. Neste grupo, 60 (47,6%) eram do GC, 39 tinham BE (30,9%) e 27 DMl (21,4%). Os casos soropositivos foram encaminhados para biópsia intestinal por endoscopia digestiva alta. Dos 126 pacientes, 6 (4,8%) apresentaram anticorpo TTG IgA positivo, dos quais 1 (1,7%) pertencia ao GC e 5 (7,6%) ao grupo com DMl ou BE (analisados em conjunto). Todos os pacientes com TTG IgA positivo tiveram histopatologia compatível com DC. Pacientes com DMl e BE apresentaram um odds ratio (OR) de 7,37 e 3,18, respectivamente, para DC. A prevalência de DC na população pediátrica com BE ou DMl foi 4,5 vezes maior que na população geral. Este achado sugere que o screening para DC deva ser implementado rotineiramente em pacientes pediátricos com DMl ou BE. / The prevalence of celiac disease (CD) is increasing globally in recent decades. Individuals belonging to the so-called groups at risk, such as diabetic type 1 and children with short stature, have a higher probability to express this autoimmune disease of the intestinal tract, often under an asymptomatic form, although can evolve with chronic complications such as osteoporosis and intestinal malignant neoplasms, if not diagnosed and treated early. This study evaluates the prevalence of celiac disease in children belonging to groups at risk, with type 1 diabetes mellitus (DM1) or with short stature (SS), based on a research carried out at a specialized endocrinology unit and at a private pediatric clinic, in Juiz de Fora, MG. This is an observational and cross-sectional study, conducted since January 2012 through April 2016. A total of 225 patients, between 2 and 16 years of age, were invited to participate: 104 were healthy (control group - CG), while 58 were DMl and 63 had SS. Of this total, 126 (56%) attended for the dosage of the tissue anti-transglutaminase antibody IgA (tTG-IgA) and serum IgA. In this group, 60 (47.6%) were CG, 39 had SS (30.9%) and 27 (21.4%) DM1. The HIV-positive cases were submitted to an intestinal biopsy by upper gastrointestinal endoscopy. Among 126 patients, 6 (4.8%) showed positive IgA-tTG antibody, of which 1 (1.7%) belonged to the CG and 5 (7.6%) to the DMl or SS group (considered together). All the patients with tTG-IgA positive had histopathology compatible with CD. Patients with DMl and SS presented an odds ratio (OR) of 7.37 and 3.18, respectively, for CD. The prevalence of CD in the pediatric population with SS or DMl was 4.5 times higher than in the general population. This finding suggests that the screening for CD should be implemented routinely in pediatric patients with DMl or SS.

Orientador: Helena Maria André Bolini / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Engenharia de Alimentos / Made available in DSpace on 2018-08-24T18:50:07Z (GMT). No. of bitstreams: 1 Alencar_NataliaManzattiMachado_M.pdf: 2756494 bytes, checksum: 6889689f69e2c7b5b689ef411223c515 (MD5) Previous issue date: 2014 / Resumo: Na atualidade a doença celíaca atinge aproximadamente 1% da população do mundo, e cerca de 3,1% dos pacientes com diabetes mellitus tipo I. A doença celíaca é caracterizada pela atrofia da mucosa intestinal na parte proximal e pela permanente intolerância ao glúten. Seu tratamento consiste em uma dieta isenta de glúten. Novas estratégias tem sido utilizadas para a fabricação de produtos de panificação isentos de glúten e sacarose, que se referem à utilização de pseudocereais, tais como amaranto e quinoa e edulcorantes, como por exemplo, sucralose e estévia. Diante disso, o objetivo desse estudo foi analisar a incorporação de farinha de amaranto e quinoa e edulcorantes (sucralose, estévia, acessulfame-k) no estudo do perfil sensorial e físico-químico em 6 amostras de pães isento de glúten e de sacarose. Os pães foram formulados contendo 20% farinha de amaranto e quinoa como substituto parcial da composição de amidos, sucralose, estévia e sucralose/acessulfame-K como edulcorantes substitutos da sacarose. Para compor o estudo de análise sensorial foram realizados Análise Descritiva Quantitativa (ADQ), teste de aceitação e análise tempo-intensidade para os estímulos gosto doce e amargo. O perfil físico-químico foi determinado por meio de volume específico do pão, cor, firmeza, atividade de água, composição centesimal, energia bruta e análise de imagem dos alvéolos. A análise estatística foi composta por Análise de Variância (ANOVA), teste de médias de Tukey ao nível de 5% de significância. Foi realizada uma correlação com os resultados da ADQ e impressão global do teste de aceitação por meio da análise de mínimos quadrados parciais (PLS). A ADQ foi realizada por 12 assessores, que geraram 24 termos descritores. Os pães com amaranto e quinoa foram percebidos com aroma e sabor característico desses pseudocereais, coloração marrom da casca do pão e maciez. No teste de consumidor verificou-se que a amostra com farinha de amaranto com sucralose foi a que obteve maior aceitação pelos consumidores. As análises-físico-químicas mostraram que os edulcorantes e as farinhas de amaranto e quinoa resultaram em bons substitutos para sacarose e amidos, respectivamente. A análise tempo-intensidade identificou um comportamento similar para a percepção do gosto doce entre as amostras. Quanto à percepção do gosto amargo, os pães de quinoa com edulcorantes sucralose e sucralose/acessulfame-K apresentaram maior intensidade máxima para esse estímulo. A correlação por PLS revelou que os atributos aroma e sabor de amaranto foram direcionadores de preferência positivos. Por meio desses resultados observa-se que a incorporação de farinha de quinoa e amaranto e edulcorantes em pães sem glúten e sacarose foi eficiente no desenvolvimento dos pães. Assim a pesquisa possibilitou o desenvolvimento de pães para uma população específica, ou seja, os celíacos, diabéticos ou ambos / Abstract: Nowadays the celiac disease reaches nearly 1% of the world population, and almost 3,1% of the patients that have mellitus type I diabetes are affected by this disease. It is characterized by the atrophy of intestinal mucosa in the proximal part and permanent gluten intolerance. The treatment is a gluten free diet. Recent studies have shown new strategies for the gluten free or/and sugar free baked products, with pseudocereals amaranth; quinoa and sweeteners as sucralose and stevia. The objective of this study was analyze the partial replacement of amaranth and quinoa flour incorporation and sucrose replacement with sweeteners (sucralose, stevia and acesulfame-K) in gluten and sucrose free bread in the sensorial and physicochemical profile in 6 samples. Different types of breads where produced with either 20% amaranth or quinoa flour replacing wheat flour and sucralose, stevia and a blend of sucralose/acesulfame-K as sucrose replacers. The sensory evaluations were performed by means of Quantitative Descriptive Analysis (QDA), acceptance test, time intensity analysis for the sweet and bitter stimuli. Physicochemical analyses were performed by specific volume, colour, firmness, water activity, proximate composition, gross energy and image analysis of the alveoli. Statistical data were statistically analised by Analysis of Variance (ANOVA) and Tukey¿s test average (in p<0.05 of significance level). Sensory profile by QDA and overall impression were correlated obtained in the partial least square analysis (PLS) correlations technique. The QDA comprised which 12 panelists and created 24 descriptive terms. The bread samples with amaranth and quinoa were identified with characteristic¿s pseudocereals aroma and taste, brown bread skin color and soft. In the acceptance test, samples with amaranth and sucralose were preferred (p<0,05). The physicochemical analyses showed the sweeteners and the amaranth and quinoa flour were good replacers for sucrose and starch respectively. Time-intensity analysis identified a substitute similar behavior concerning to the sweet taste perception among the samples, while the perception of bitterness in the quinoa with sweeteners sucralose and sucralose/acesulfame-K presented maximum intensity for that stimuli. The correlations by PLS analysis revealed that the aroma and taste amaranth attributes detected the positive preference. From these results it is possible to conclude that the incorporation of quinoa and amaranth flour and sweeteners in breads without gluten and sucrose was efficient in the development the bread for a specific population, in other words, celiac and diabetics / Mestrado / Consumo e Qualidade de Alimentos / Mestra em Alimentos e Nutrição

Introduction: HLA class II system presents one of the most important mechanism in immune system, which is able to recognise pathogens and damaged cells. Some HLA class II alleles are associated with autoimmune diseases, for example celiac disease, which is typical by chronic inflammation of small intestine and other following symptoms. The risk HLA class II variants are DQ2 and DQ8. Epigenetic mechanisms that regulates gene expression, especially methylation of cytosine in promoter region of DQ2 and/or DQ8 alleles, could have influence on development of T lymphocytes in the thymus, where T-lymphocytes develop and pass a few stages in, and only the survival clones can be part of function immune system. Aim: The aim of this study is to compare methylation level of promoter regions of HLA DQ2 and DQ8 alleles between celiac patients and healthy controls. Another goal is to compare expression level of DQ2 and DQ8 variants between these two groups. Methods: DNA and RNA were isolated from full blood of two sets of donors. DNA was converted by bisulphite conversion and then amplified by Nested PCR. The PCR product was cloned to bacteria. Than positive colonies were selected. Subsequent methylation analysis was performed. RNA was converted to cDNA by Reverse transcription. Relative expression was analyzed...

This thesis contains information about gluten free food market. It describes all main actors and also different types of business which can sell or manufacture gluten free food. Great emphasis is placed on understanding needs of "gluten free" customers identifying behavior which differentiate them inside this segment and also between regular customers. It also discovers opportunities and challenges on this market. Based on collected information it predicts possible future development.

Recent reductions in healthcare funding in the United States has pressured clinical laboratories to provide the same quality of diagnostic testing with fewer resources. Testing cascades have been developed to assist in the diagnosis of various illnesses, which use fewer tests and subsequently reduce costs. However, the cost effectiveness of a celiac disease (CD) testing cascade compared to a panel is currently unknown. Therefore, the purpose of this study was to determine if a CD testing cascade was equivalent to a panel in identifying patients deemed likely for CD, and to compare their cost effectiveness in a sample of symptomatic patients from Northeast Tennessee. A retrospective analysis using a CD testing cascade was performed on 933 outpatient samples referred to our laboratory from 2012 to 2017 with a request for a celiac disease serology panel. The seroprevalence of CD for the panel and the cascade were the same in this population (1.82%, 95% binomial confidence interval: 1.06% to 2.90%). The total cost of the CD cascade was 268% less than the cost of the panel resulting in a savings of $44,705, which translates to a savings of $47.92/patient. Based on these findings, we recommend utilization of the cascade to identify patients with likely CD. In the future, creative use of novel testing strategies can have significant contributions to healthcare reform and afford patients more cost-effective clinical diagnostic testing.

Health Tech company Dynamic Code AB provides a PCR test for determination of HLA DQ-genes connected to development of celiac disease. The PCR method is probe based and in real time and is at this time carried through on the, somewhat outdated, PCR instrument from Thermo Fisher/Applied Biosystems called 7300 Real-Time PCR System. The run time for this analysis on the instrument is 1 hour and 50 minutes. The Master Mix in use is TaqMan™ Gene Expression Master Mix, from the same manufacturer. Moving on to a more modern PCR instrument is a natural step for the company and is favourable in several regards, one of them being the run time that will be cut by 50 minutes, allowing for more samples to be analysed in the same amount of time. The objective is to move the HLA analysis to Thermo Fisher’s QuantStudio™ 6 and 7 Flex Systems and at the same time change the Master Mix to SolisFast® Probe qPCR Mix (Purple) from Solis BioDyne, in order to achieve better accuracy as this Master Mix is more compatible with the latter instrument, along with reducing reagent cost as it is less expensive. In order to find the optimal primer and probe concentration for each target included in the HLA analysis, their concentrations were varied and tested with the new Master Mix on the new instrument. PCR instrument transfer and Master Mix change was successful and validation experiments showed a 98,9% accuracy for the new method compared to the original method.

Celiac disease, a common autoimmune disease, affects ~1% of Americans. Treatment requires strict elimination of gluten, proteins found in wheat, rye, and barley. Individuals with celiac disease have been shown to have a lower quality of life than others without it. However, their quality of life has been known to improve with adherence to the gluten-free diet. Other than gluten-free diet adherence, little research has been completed on how specific eating patterns may impact the lives of individuals with celiac disease. In the general population, diet quality has been associated with health-related quality of life, where quality of life has been predictive of other outcomes, like mortality. Research in the general population has also shown an association between increased consumption of ultra-processed foods and adverse health outcomes, including obesity, cancer, and premature mortality, but none have explored its relation to quality of life. Among individuals with celiac disease, no studies have explored the relationship between diet quality or ultra-processing resulting from strictly adhering to a gluten-free diet and celiac disease-specific quality of life. This dissertation describes the eating patterns of a sample of 50 adults and 30 teens with celiac disease (the “sample”) to understand what they were eating, as well as the relationship between their diet quality and level of food processing to quality of life. Results were compared to a representative sampling of the population in the United States from the National Health and Nutrition Examination Survey (“NHANES”). The sample had room for improvement in their diet quality and levels of ultra-processing but performed favorably compared with NHANES. Using the Healthy Eating Index, the majority had scores considered suboptimal (mostly moderate scoring). However, using the Alternate Mediterranean Diet score, fewer had suboptimal scores (mostly moderate to high scoring). Differences between the measures’ scores reflected: (1) variations in measurement criteria, and (2) separate weights applied to those criteria. The sample had ultra-processed food consumption within the range associated with adverse health outcomes in some studies. With the exception of low folate and high lipids, most of the sample’s nutrient concerns reflected those in NHANES. The sample’s diet patterns were most similar to those in NHANES who had reported prior celiac disease diagnosis and were adhering to a gluten-free diet, with patterns significantly more favorable to other NHANES groups. In the general population, there was a consistent relationship with both higher Alternate Mediterranean Diet score and lower levels of ultra-processed food consumption as a percent of energy to better quality of life. Similar but less robust trends were found with the sample. Overall, results suggested that both higher adherence to healthier diet patterns (for example, more produce, legumes, nuts, whole grains, and less saturated fat) and lower levels of ultra-processing were associated with higher quality of life.

The aim of thesis was monitoring of changes in the content of gluten proteins in the biotechnological process of beer production. During the production process of wheat and barley beer, the samples were collected and analysed using the electrophoresis and immunoassay method. The results of the analyses were compared with commercial Czech beers. The theoretical part contains description and composition of gluten proteins, malt and beer technology, the changes that occur in this process, and methods of gluten proteins analysis. The experimental part contains procedures for laboratory production of barley and wheat beer and analyses of gluten proteins. To identify the individual gluteal protein fraction acid and SDS electrophoresis methods were used. For quantification, enzyme immunoassay was used and evaluated spectrophotometrically. The identification of the gluten‘s fractions by electrophoretic methods has been shown to be less specific for samples with lower content of gluten proteins and for barley specimens. A decrease in the concentration of gliadins and glutenins in the beer production process was demonstrated. A significant change was found during wort production with 98% decrease of gluten content compared to the feedstock and during the fermentation, when the gluten concentration dropped below 10 mg/kg. This value is acceptable from the legislation for products labelled „gluten-free“.